JPWO2019234576A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019234576A5 JPWO2019234576A5 JP2020568373A JP2020568373A JPWO2019234576A5 JP WO2019234576 A5 JPWO2019234576 A5 JP WO2019234576A5 JP 2020568373 A JP2020568373 A JP 2020568373A JP 2020568373 A JP2020568373 A JP 2020568373A JP WO2019234576 A5 JPWO2019234576 A5 JP WO2019234576A5
- Authority
- JP
- Japan
- Prior art keywords
- bispecific antibody
- seq
- item
- binding moiety
- ceacam5
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 91
- 238000000034 method Methods 0.000 claims description 70
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 64
- 206010028980 Neoplasm Diseases 0.000 claims description 58
- 201000011510 cancer Diseases 0.000 claims description 48
- 210000004027 cell Anatomy 0.000 claims description 40
- 206010057249 Phagocytosis Diseases 0.000 claims description 31
- 230000008782 phagocytosis Effects 0.000 claims description 31
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 28
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 28
- 102000047627 human CEACAM5 Human genes 0.000 claims description 27
- 210000004881 tumor cell Anatomy 0.000 claims description 19
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 206010006187 Breast cancer Diseases 0.000 claims description 16
- 208000026310 Breast neoplasm Diseases 0.000 claims description 16
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 16
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 16
- 206010017758 gastric cancer Diseases 0.000 claims description 16
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 16
- 229920001542 oligosaccharide Polymers 0.000 claims description 16
- 150000002482 oligosaccharides Chemical class 0.000 claims description 16
- 201000002528 pancreatic cancer Diseases 0.000 claims description 16
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 16
- 201000011549 stomach cancer Diseases 0.000 claims description 16
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 15
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 238000003556 assay Methods 0.000 claims description 11
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 9
- 102000044459 human CD47 Human genes 0.000 claims description 9
- 238000003384 imaging method Methods 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 7
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 claims description 7
- 210000002540 macrophage Anatomy 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 206010057248 Cell death Diseases 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 230000009089 cytolysis Effects 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 5
- 102000046810 human CEACAM6 Human genes 0.000 claims description 5
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims description 4
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 4
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 108010062802 CD66 antigens Proteins 0.000 claims description 2
- 241000282567 Macaca fascicularis Species 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims 1
- 102000034285 signal transducing proteins Human genes 0.000 claims 1
- 108091006024 signal transducing proteins Proteins 0.000 claims 1
- 230000001965 increasing effect Effects 0.000 description 21
- 125000003275 alpha amino acid group Chemical group 0.000 description 14
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 12
- 208000015634 Rectal Neoplasms Diseases 0.000 description 9
- 230000000112 colonic effect Effects 0.000 description 9
- 206010038038 rectal cancer Diseases 0.000 description 9
- 201000001275 rectum cancer Diseases 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 5
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 5
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 102100024775 Beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 108010087667 beta-1,4-mannosyl-glycoprotein beta-1,4-N-acetylglucosaminyltransferase Proteins 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- 101150023212 fut8 gene Proteins 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18175655 | 2018-06-03 | ||
| EP18175656 | 2018-06-03 | ||
| EP18175658 | 2018-06-03 | ||
| EP18175655.2 | 2018-06-03 | ||
| EP18175656.0 | 2018-06-03 | ||
| EP18175658.6 | 2018-06-03 | ||
| EP18175657.8 | 2018-06-03 | ||
| EP18175657 | 2018-06-03 | ||
| EP18188792 | 2018-08-13 | ||
| EP18188790.2 | 2018-08-13 | ||
| EP18188788.6 | 2018-08-13 | ||
| EP18188788 | 2018-08-13 | ||
| EP18188792.8 | 2018-08-13 | ||
| EP18188790 | 2018-08-13 | ||
| EP18190983.9 | 2018-08-27 | ||
| EP18190983 | 2018-08-27 | ||
| PCT/IB2019/054559 WO2019234576A1 (en) | 2018-06-03 | 2019-05-31 | Bispecific antibodies against ceacam5 and cd47 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021525544A JP2021525544A (ja) | 2021-09-27 |
| JP2021525544A5 JP2021525544A5 (https=) | 2022-06-07 |
| JPWO2019234576A5 true JPWO2019234576A5 (https=) | 2022-06-07 |
| JP7403479B2 JP7403479B2 (ja) | 2023-12-22 |
Family
ID=66752156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568373A Active JP7403479B2 (ja) | 2018-06-03 | 2019-05-31 | Ｃｅａｃａｍ５およびｃｄ４７に対する二重特異性抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20210221908A1 (https=) |
| EP (1) | EP3802599B1 (https=) |
| JP (1) | JP7403479B2 (https=) |
| CN (1) | CN112566938B (https=) |
| AU (1) | AU2019281358B2 (https=) |
| ES (1) | ES2973518T3 (https=) |
| MX (1) | MX2020013122A (https=) |
| WO (1) | WO2019234576A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3802599B1 (en) | 2018-06-03 | 2023-12-20 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
| CN114786776B (zh) | 2019-09-18 | 2026-03-24 | 拉姆卡普生物阿尔法股份公司 | 针对ceacam5和cd3的双特异性抗体 |
| EP3831849A1 (en) * | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
| JP7369297B2 (ja) * | 2019-12-17 | 2023-10-25 | ファイザー・インク | Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用 |
| CN111018969A (zh) * | 2019-12-27 | 2020-04-17 | 上海药明生物技术有限公司 | 采用轻链select联合层析色谱纯化双特异性抗体的方法 |
| ES2967381T3 (es) | 2020-12-18 | 2024-04-30 | Lamkap Bio Beta Ag | Anticuerpos biespecíficos contra CEACAM5 y CD47 |
| CA3212599A1 (en) * | 2021-03-22 | 2022-09-29 | Novimmune S.A. | Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof |
| IL305827A (en) | 2021-03-22 | 2023-11-01 | Novimmune Sa | Bispecific antibodies targeting CD47 and PD-L1 and methods of using them |
| CN115819596A (zh) * | 2021-09-17 | 2023-03-21 | 优迈生物科技(连云港)有限公司 | 一种靶向人ceacam5/6的抗体、制备方法和应用 |
| WO2023070353A1 (en) * | 2021-10-27 | 2023-05-04 | Adagene Pte. Ltd. | Anti-cd47 antibodies and methods of use thereof |
| IL314916A (en) * | 2022-03-07 | 2024-10-01 | Novimmune Sa | Bispecific CD28 antibodies for targeted T cell activation |
| CN119095873A (zh) | 2022-03-14 | 2024-12-06 | 拉姆卡普生物伽马股份公司 | 用于靶向杀伤GPC3阳性恶性细胞的双特异性GPC3xCD28和GPC3xCD3抗体及其组合 |
| US20250230256A1 (en) | 2022-06-16 | 2025-07-17 | Lamkap Bio Beta Ltd | Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3 |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| JP3535868B2 (ja) | 2000-10-05 | 2004-06-07 | 松下電器産業株式会社 | 判定レベル設定方法、およびデータ受信装置 |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US20020165360A1 (en) | 2000-11-30 | 2002-11-07 | Junghans Richard P. | Chimeric effector cell receptors against carcinoembryonic antigen |
| EP2180044A1 (en) | 2001-08-03 | 2010-04-28 | GlycArt Biotechnology AG | Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| JP4820055B2 (ja) | 2001-12-27 | 2011-11-24 | グライコフィ， インコーポレイテッド | 哺乳動物型糖質構造を操作するための方法 |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
| EA200401325A1 (ru) | 2002-04-09 | 2005-04-28 | Киова Хакко Когио Ко., Лтд. | Клетки с модифицированным геномом |
| US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| JP4832719B2 (ja) | 2002-04-09 | 2011-12-07 | 協和発酵キリン株式会社 | ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬 |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| US7232888B2 (en) | 2002-07-01 | 2007-06-19 | Massachusetts Institute Of Technology | Antibodies against tumor surface antigens |
| DE60333201D1 (de) | 2002-09-12 | 2010-08-12 | Greenovation Biotech Gmbh | Verfahren zur herstellung von proteinen |
| US7781197B2 (en) | 2002-12-20 | 2010-08-24 | Greenovation Biotech Gmbh | Transformed bryophyte cell having disrupted endogenous alpha 1,3-fucosyl and beta 1,2-xylosyl transferase encoding nucleotide sequences for the production of heterologous glycosylated proteins |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス，インコーポレーテッド | 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法 |
| CN103540600B (zh) | 2003-01-22 | 2017-12-01 | 罗氏格黎卡特股份公司 | 融合构建体及其用来生产Fc受体结合亲和性和效应子功能提高的抗体的用途 |
| WO2005018669A1 (en) | 2003-08-18 | 2005-03-03 | Macrogenics, Inc. | Fcϝriib-specific antibodies and methods of use thereof |
| CN1871259A (zh) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | 具有改变的效应物功能的经改进的抗体和制备它的方法 |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| CA2548817A1 (en) | 2003-12-04 | 2005-06-23 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| US20050266425A1 (en) * | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
| EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| US8435517B2 (en) | 2008-09-17 | 2013-05-07 | Xencor, Inc. | Compositions and methods for treating IgE-mediated disorders |
| WO2005110474A2 (en) | 2004-05-10 | 2005-11-24 | Macrogenics, Inc. | HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
| WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
| CN103172731A (zh) | 2004-07-15 | 2013-06-26 | 赞科股份有限公司 | 优化的Fc变体 |
| EP1778726A4 (en) | 2004-08-16 | 2009-03-18 | Medimmune Inc | INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| EP1810035A4 (en) | 2004-11-10 | 2010-03-17 | Macrogenics Inc | GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION |
| CA2602663A1 (en) | 2005-03-31 | 2006-10-05 | Xencor, Inc. | Fc variants with optimized properties |
| WO2006116260A2 (en) | 2005-04-26 | 2006-11-02 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| WO2007008943A2 (en) | 2005-07-08 | 2007-01-18 | Xencor, Inc. | Optimized anti-ep-cam antibodies |
| HUE029465T2 (en) | 2005-08-10 | 2017-02-28 | Macrogenics Inc | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| WO2007041635A2 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| WO2007044616A2 (en) | 2005-10-06 | 2007-04-19 | Xencor, Inc. | Optimized anti-cd30 antibodies |
| AU2006301492B2 (en) | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
| KR20080068089A (ko) | 2005-10-21 | 2008-07-22 | 지티씨바이오쎄라퓨틱스,인크. | 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및사용 방법 |
| LT1976880T (lt) | 2005-12-21 | 2016-10-10 | Amgen Research (Munich) Gmbh | Farmacinės kompozicijos, pasižyminčios atsparumu tirpiam cea |
| CA2644903A1 (en) | 2006-03-10 | 2007-09-20 | Macrogenics, Inc. | Identification and engineering of antibodies with variant heavy chains and methods of using same |
| IL177158A0 (en) | 2006-07-30 | 2008-01-20 | Assaf Klar | Method for designing and implementing improved longitudinal flexibility multilayered pipeline |
| PL2383297T3 (pl) | 2006-08-14 | 2013-06-28 | Xencor Inc | Zoptymalizowane przeciwciała ukierunkowane na CD19 |
| WO2008036688A2 (en) | 2006-09-18 | 2008-03-27 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
| WO2008121160A2 (en) | 2006-11-21 | 2008-10-09 | Xencor, Inc. | Optimized antibodies that target cd5 |
| WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
| WO2008091798A2 (en) | 2007-01-22 | 2008-07-31 | Xencor, Inc. | Optimized ca9 antibodies and methods of using the same |
| EP2125893A2 (en) | 2007-01-23 | 2009-12-02 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
| WO2008098115A2 (en) | 2007-02-07 | 2008-08-14 | Xencor, Inc. | Optimized igf-1r antibodies and methods of using the same |
| RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| WO2008119565A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific binding domain |
| WO2008119566A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
| CA2693053C (en) | 2007-05-30 | 2021-01-05 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| US8163551B2 (en) | 2008-05-02 | 2012-04-24 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| JP6126782B2 (ja) | 2008-10-01 | 2017-05-10 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハー | 異種間特異的ｐｓｍａ×ｃｄ３二重特異性単鎖抗体 |
| CA2738568C (en) | 2008-10-01 | 2024-02-20 | Micromet Ag | Cross-species-specific single domain bispecific single chain antibody |
| PL2352763T5 (pl) | 2008-10-01 | 2023-01-30 | Amgen Research (Munich) Gmbh | Bispecyficzne przeciwciała jednołańcuchowe o specyficzności wobec antygenów docelowych o dużej masie cząsteczkowej |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| EP3009455A1 (en) | 2009-09-16 | 2016-04-20 | Immunomedics Inc. | Class i anti-cea antibodies and uses thereof |
| PL2606064T3 (pl) | 2010-08-16 | 2015-07-31 | Novimmune Sa | Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał |
| RS56793B1 (sr) | 2011-03-02 | 2018-04-30 | Roche Glycart Ag | Cea antitela |
| US20140242081A1 (en) | 2011-07-18 | 2014-08-28 | Micromet Ag | Dosing regimens for treatment of cea-expressing cancers |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| EP2768857B1 (en) | 2011-10-19 | 2020-01-01 | NovImmune SA | Methods of purifying antibodies |
| US20140140989A1 (en) | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| EP2904016B1 (en) * | 2012-10-08 | 2018-11-14 | Roche Glycart AG | Fc-free antibodies comprising two fab-fragments and methods of use |
| HUE033369T2 (en) | 2012-11-20 | 2017-11-28 | Sanofi Sa | Anti-ceacam5 antibodies and uses thereof |
| CN105121467B (zh) * | 2012-12-03 | 2019-07-05 | 诺夫免疫股份有限公司 | 抗cd47抗体及其使用方法 |
| US9738722B2 (en) | 2013-01-15 | 2017-08-22 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| MX375359B (es) | 2013-02-26 | 2025-03-06 | Roche Glycart Ag | Moléculas biespecíficas de unión a antígeno activadoras de células t. |
| ES2898627T3 (es) | 2013-04-29 | 2022-03-08 | Univ Leland Stanford Junior | Uso de agentes anti-CD47 para mejorar la inmunización |
| CA2920113A1 (en) | 2013-08-20 | 2015-02-26 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of a pd-1 antagonist and dinaciclib |
| ES3012974T3 (en) | 2014-01-08 | 2025-04-10 | Univ Leland Stanford Junior | Targeted therapy for lung cancer |
| WO2015112534A2 (en) | 2014-01-21 | 2015-07-30 | Medimmune, Llc | Compositions and methods for modulating and redirecting immune responses |
| ES2916923T3 (es) | 2014-07-11 | 2022-07-06 | Ventana Med Syst Inc | Anticuerpos anti-PD-L1 y usos diagnósticos de los mismos |
| WO2016036678A1 (en) | 2014-09-02 | 2016-03-10 | Medimmune, Llc | Formulations of bispecific antibodies |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| PL238187B1 (pl) | 2015-01-23 | 2021-07-19 | Helix Biopharma Corp | Koniugaty przeciwciało-ureaza dla celów terapeutycznych |
| PT3274370T (pt) * | 2015-03-23 | 2020-01-30 | Bayer Pharma AG | Anticorpos anti-ceacam6 e utilizações dos mesmos |
| PT3277821T (pt) | 2015-03-31 | 2019-10-31 | Novimmune Sa | Método para otimizar a montagem e produção de complexos proteicos hetero-multiméricos |
| DE102015212888A1 (de) | 2015-07-09 | 2017-01-12 | BSH Hausgeräte GmbH | Geschirrspülmaschine mit einer Trocknungseinrichtung |
| WO2017027422A1 (en) | 2015-08-07 | 2017-02-16 | Alexo Therapeutics Inc. | Constructs having a sirp-alpha domain or variant thereof |
| EP3356410B1 (en) | 2015-10-02 | 2021-10-20 | F. Hoffmann-La Roche AG | Bispecific anti-ceaxcd3 t cell activating antigen binding molecules |
| EP3165536A1 (en) | 2015-11-09 | 2017-05-10 | Ludwig-Maximilians-Universität München | Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition |
| GB2546072B (en) | 2016-01-05 | 2019-07-10 | Bja Trading Ltd | Attachment assembly and method of using same |
| JP6949030B2 (ja) | 2016-01-08 | 2021-10-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｐｄ−１軸結合アンタゴニスト及び抗ｃｅａ／抗ｃｄ３二重特異性抗体を用いたｃｅａ陽性がんの治療方法 |
| EP3747906A1 (en) | 2016-01-11 | 2020-12-09 | Forty Seven, Inc. | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies |
| AR112048A1 (es) | 2016-05-09 | 2019-09-18 | Celgene Corp | Anticuerpos cd47 y métodos de uso de los mismos |
| CN107556386A (zh) * | 2016-06-30 | 2018-01-09 | 中国科学院深圳先进技术研究院 | 抗EGFRvIII和CD3特异性双靶向抗体、含双靶向抗体表达盒的微环DNA及应用 |
| GB201611530D0 (en) * | 2016-07-01 | 2016-08-17 | Alligator Bioscience Ab | Novel polypeptides |
| WO2018098384A1 (en) * | 2016-11-22 | 2018-05-31 | Regents Of The University Of California | Segregation modulation for immunotherapy |
| EP3802599B1 (en) * | 2018-06-03 | 2023-12-20 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
| ES2967381T3 (es) * | 2020-12-18 | 2024-04-30 | Lamkap Bio Beta Ag | Anticuerpos biespecíficos contra CEACAM5 y CD47 |
-
2019
- 2019-05-31 EP EP19728547.1A patent/EP3802599B1/en active Active
- 2019-05-31 US US15/734,962 patent/US20210221908A1/en not_active Abandoned
- 2019-05-31 WO PCT/IB2019/054559 patent/WO2019234576A1/en not_active Ceased
- 2019-05-31 US US16/428,539 patent/US11555071B2/en active Active
- 2019-05-31 ES ES19728547T patent/ES2973518T3/es active Active
- 2019-05-31 MX MX2020013122A patent/MX2020013122A/es unknown
- 2019-05-31 AU AU2019281358A patent/AU2019281358B2/en active Active
- 2019-05-31 JP JP2020568373A patent/JP7403479B2/ja active Active
- 2019-05-31 CN CN201980051452.3A patent/CN112566938B/zh active Active
-
2022
- 2022-12-08 US US18/063,477 patent/US20240084001A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021525544A5 (https=) | ||
| WO2020013170A1 (ja) | 抗ＳＩＲＰα抗体 | |
| EP3652216A1 (en) | Checkpoint inhibitor bispecific antibodies | |
| CN116261590B (zh) | 抗cd3抗体以及其用途 | |
| JPWO2019234576A5 (https=) | ||
| JP7843824B2 (ja) | 抗体および使用方法 | |
| AU2021400227A9 (en) | Bispecific antibodies against ceacam5 and cd47 | |
| JP2025524386A (ja) | 抗ｃｌｄｎ１８．２抗体を含む二重特異性抗体、並びにその医薬組成物及び使用 | |
| KR20230006823A (ko) | Her2를 표적화하는 항원 결합 구조체 및 이의 용도 | |
| CA3181579A1 (en) | Bifunctional protein against pd-1 and tgf-.beta. | |
| WO2021214329A1 (en) | Composition comprising an ige antibody | |
| KR20250044359A (ko) | 항-ccr8 항체 및 사용 방법 | |
| WO2023098785A1 (zh) | 抗4-1bb抗体及其用途 | |
| TW202330627A (zh) | 特異性結合cd47和her2的雙特異性抗體及其用途 | |
| JP7748389B2 (ja) | 抗ｃｄ４７抗体およびその使用 | |
| TW202434284A (zh) | 使用抗 CTLA4 抗體與 Pembrolizumab 組合治療癌症的方法 | |
| WO2022057910A1 (en) | Combination therapies targeting c5ar and pd-1/pd-l1 pathways | |
| RU2020143543A (ru) | Биспецифические антитела против ceacam5 и cd47 | |
| CN116547307A (zh) | 结合cd38的抗体及其用途 | |
| US12606617B2 (en) | Composition comprising an IgE antibody | |
| WO2025157223A1 (en) | Multispecific antibodies and uses thereof | |
| US20250326849A1 (en) | COMBINATION OF A FcyRIIB- AND A TUMOR ANTIBODY FOR USE IN THE TREATMENT OF AN FcyRIIB-NEGATIVE CANCER | |
| WO2025062392A1 (en) | Anti-ilt3 blockade combinations | |
| WO2025232896A1 (zh) | 药物组合及用途 | |
| TW202417484A (zh) | 異多聚體蛋白質及其製備方法 |